​

MannKind (MNKD) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

MNKD Stock Forecast

MannKind (MNKD) stock forecast, based on 18 Wall Street analysts, predicts a 12-month average price target of $9.00, with a high of $9.00 and a low of $9.00. This represents a 219.15% increase from the last price of $2.82.

$2 $3 $4 $5 $6 $7 $8 $9 High: $9 Avg: $9 Low: $9 Last Closed Price: $2.82

MNKD Stock Rating

MannKind stock's rating consensus is Buy, based on 18 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (44.44%), 3 Hold (16.67%), 7 Sell (38.89%), and 0 Strong Sell (0.00%).

Buy
Total 18 0 7 3 8 Strong Sell Sell Hold Buy Strong Buy

MNKD Price Target Upside V Benchmarks

TypeNameUpside
StockMannKind219.15%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts--4
Avg Price Target--$9.25
Last Closing Price$2.82$2.82$2.82
Upside/Downside--228.01%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 26-81--9
Feb, 2618---9
Jan, 2618---9
Dec, 2518---9
Nov, 2526---8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 24, 2025Truist Financial$9.00$5.0378.93%219.15%
Sep 02, 2025H.C. Wainwright$11.00$5.7491.64%290.07%
Aug 26, 2025Douglas MiehmRBC Capital$8.00$4.00100.00%183.69%
Aug 25, 2025H.C. Wainwright$9.00$3.90130.77%219.15%
Aug 28, 2024Steven LichtmanOppenheimer$12.00$5.38123.05%325.53%
Oct 10, 2023Andreas ArgyridesWedbush$10.00$4.23136.41%254.61%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 08, 2026H.C. WainwrightBuyBuyhold
Nov 10, 2025H.C. WainwrightBuyBuyhold
Aug 26, 2025RBC CapitalOutperformOutperformhold
Aug 25, 2025H.C. WainwrightBuyBuyhold
Dec 19, 2024RBC CapitalOutperformupgrade
Aug 28, 2024OppenheimerOutperformOutperformhold
Jun 12, 2024Rodman & RenshawBuyinitialise
Oct 10, 2023WedbushOutperforminitialise

Financial Forecast

EPS Forecast

Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.37$-0.44$-0.04$0.10$0.02---
Avg Forecast$-0.27$-0.32$-0.05$0.10$0.25$0.33$0.40$0.53
High Forecast$-0.26$-0.31$-0.01$0.11$0.36$0.50$0.62$0.55
Low Forecast$-0.28$-0.33$-0.08$0.08$0.17$0.22$0.28$0.50
Surprise %37.04%37.50%-20.00%--92.00%---

Revenue Forecast

$50M $150M $250M $350M $450M $550M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$75.44M$99.77M$198.96M$285.50M$348.97M---
Avg Forecast$80.01M$99.59M$194.00M$280.83M$333.70M$383.98M$429.23M$503.48M
High Forecast$82.46M$102.54M$197.56M$281.46M$344.79M$384.57M$432.20M$519.82M
Low Forecast$77.35M$96.77M$191.12M$280.19M$322.61M$383.39M$426.25M$483.84M
Surprise %-5.71%0.19%2.56%1.67%4.57%---

Net Income Forecast

$-100M $-40M $20M $80M $140M $200M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-80.93M$-87.40M$-11.94M$27.59M$5.86M---
Avg Forecast$-54.87M$-73.49M$-11.94M$26.21M$78.05M$100.68M$122.36M$141.52M
High Forecast$-43.90M$-58.79M$-9.55M$30.35M$96.70M$132.29M$165.34M$147.49M
Low Forecast$-65.84M$-88.18M$-14.33M$22.07M$45.51M$58.21M$74.67M$134.34M
Surprise %47.49%18.94%-5.26%-92.49%---

MNKD Forecast FAQ

Is MannKind stock a buy?

MannKind stock has a consensus rating of Buy, based on 18 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 3 Hold, 7 Sell, and 0 Strong Sell, reflecting a consensus that MannKind is a favorable investment for most analysts.

What is MannKind's price target?

MannKind's price target, set by 18 Wall Street analysts, averages $9 over the next 12 months. The price target range spans from $9 at the low end to $9 at the high end, suggesting a potential 219.15% change from the previous closing price of $2.82.

How does MannKind stock forecast compare to its benchmarks?

MannKind's stock forecast shows a 219.15% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for MannKind over the past three months?

  • March 2026: 0% Strong Buy, 88.89% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 11.11% Strong Buy, 88.89% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 11.11% Strong Buy, 88.89% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is MannKind’s EPS forecast?

MannKind's average annual EPS forecast for its fiscal year ending in December 2026 is $0.33, marking a 1550.00% increase from the reported $0.02 in 2025. Estimates for the following years are $0.4 in 2027, and $0.53 in 2028.

What is MannKind’s revenue forecast?

MannKind's average annual revenue forecast for its fiscal year ending in December 2026 is $383.98M, reflecting a 10.03% increase from the reported $348.97M in 2025. The forecast for 2027 is $429.22M, and $503.48M for 2028.

What is MannKind’s net income forecast?

MannKind's net income forecast for the fiscal year ending in December 2026 stands at $100.68M, representing an 1617.24% increase from the reported $5.86M in 2025. Projections indicate $122.36M in 2027, and $141.52M in 2028.